Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients.
about
Endocrinology and hormone therapy in breast cancer: selective oestrogen receptor modulators and downregulators for breast cancer - have they lost their way?Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancerSelective estrogen receptor modulators: tissue specificity and clinical utility.Arzoxifene: the evidence for its development in the management of breast cancer.Designing the ideal selective estrogen receptor modulator--an achievable goal?Beyond raloxifene for the prevention of osteoporosis and breast cancerArzoxifene: the development and clinical outcome of an ideal SERM.Bioactivation of Selective Estrogen Receptor Modulators (SERMs)Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast CancerUterine peroxidase-catalyzed formation of diquinone methides from the selective estrogen receptor modulators raloxifene and desmethylated arzoxifeneNew insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer.Selective estrogen receptor modulator BC-1 activates antioxidant signaling pathway in vitro via formation of reactive metabolitesBreast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene.
P2860
Q24810287-C6C9FEE0-48BB-471A-A6C3-A49690258B62Q26825584-9A8B6338-BB46-406B-99A9-2F44AFE4BB91Q34134828-7CDF96B7-3D9C-4EA6-9BDE-C63166C3743EQ34449901-0FE81D5F-A060-407D-9942-552CE0F74C9BQ35023776-A7BE4438-163D-48E2-86C5-424E330919E3Q36052490-BC1A05A1-A824-4C33-AED8-655D6D108F9FQ36407322-BEAE2332-2D53-4D2D-8913-445F4057FBEEQ36595120-A9A83CA7-A96A-4052-B215-0AE00DFBDBD8Q36656704-90DE15B3-16B6-42B6-A6E3-C96E5C10F570Q36828630-47A189A1-9BB9-4F14-AF1B-1A01E4F8C386Q36927087-A42381EE-469E-4423-8295-A982031199F2Q37728299-D98B45E7-5C04-4FF9-939B-C539966633ACQ51182331-9FF48548-A630-4C5D-BD35-480EBCFCC711
P2860
Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Randomized, double-blind, mult ...... static breast cancer patients.
@ast
Randomized, double-blind, mult ...... static breast cancer patients.
@en
type
label
Randomized, double-blind, mult ...... static breast cancer patients.
@ast
Randomized, double-blind, mult ...... static breast cancer patients.
@en
prefLabel
Randomized, double-blind, mult ...... static breast cancer patients.
@ast
Randomized, double-blind, mult ...... static breast cancer patients.
@en
P2093
P356
P1433
P1476
Randomized, double-blind, mult ...... astatic breast cancer patients
@en
P2093
A Llombart-Cussac
E Carrasco
L Kayitalire
P304
P356
10.1093/ANNONC/MDG368
P577
2003-09-01T00:00:00Z